EE340 Impact of Quality of Evidence on Cost-Effectiveness Outcomes for New Products: Pilot Study for a Hypothetical New Therapy for HR+/HER2- Metastatic Breast Cancer (MBC)

Parameter estimation in cost-effectiveness (CE) analyses often uses published evidence, which can be of varying quality. Parameters with poor quality of evidence (QoE) may lead to biases and/or model imprecision, resulting in potential mis-estimation of economically economically justifiable prices (EJP) and/or incremental cost-effectiveness ratios (ICER). We describe a method for assessing the impact of QoE for clinical parameters (e.g., overall survival, progression-free survival, time to treatment discontinuation), cost measures (e.g., treatment and monitoring-specific, adverse event [AE]-related costs), and health-state utilities on these CE outcomes, illustrating its use for a hypothetical new drug vs endocrine therapy in HR+/HER2- mBC.